Advanced Treatment of Type 1 Diabetes with Teplizumab: Mechanism and Clinical Efficacy
Tejas Chavan, Suresh Waghamare, Shubham Kokare & Aniruddha Madake · Asian Journal of Medical Principles and Clinical Practice · 2025
Teplizumab, a humanized anti-CD3 monoclonal antibody, has emerged as a significant advancement in the treatment of type 1 diabetes (T1D), an autoimmune disease characterized by the destruction of insulin-producing pancreatic beta cells. As the first FDA-approved disease-modifying...
Open access
Research Article
10.9734/ajmpcp/2025/v8i1262